QPPV.COM KNOWLEDGE ASSESSMENT

Darbepoetin Alfa: Erythropoietin Biology, Anaemia Treatment and Product Pharmacovigilance

Test your understanding of the concepts covered by Darbepoetin Alfa: Erythropoietin Biology, Anaemia Treatment and Product Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why is product name, presentation and batch or lot information especially valuable in darbepoetin alfa pharmacovigilance?

It proves causality in every adverse-event report It supports biological traceability and investigation of immunogenicity, quality issues, clusters and device problems It determines the patient's tumour stage It eliminates the need to record dose and route

Question 2 of 10 If neutralising anti-erythropoietin antibodies are suspected, why may switching directly to another erythropoietic protein be inappropriate?

All erythropoietic proteins have identical excipients The antibodies may cross-react with other therapeutic erythropoietic proteins Another erythropoietic protein always worsens iron deficiency Switching would permanently prevent reticulocyte measurement

Question 3 of 10 Why can an incorrect dosing interval be particularly important with darbepoetin alfa?

Its longer persistence can cause an interval error to alter cumulative exposure over a longer period It is cleared so rapidly that interval errors have no clinical effect It is administered only once in a patient's lifetime Interval errors affect only the colour of the product

Question 4 of 10 Which statement best distinguishes biological efficacy from clinical benefit in ESA treatment?

Any increase in haemoglobin is automatically a clinical benefit A biological increase in red-cell production may coexist with increased vascular risk and no improvement in major outcomes Clinical benefit is determined only by receptor-binding affinity A lack of transfusion always indicates treatment failure

Question 5 of 10 What is the appropriate immediate product-related action when signs and symptoms suggest Stevens-Johnson syndrome or toxic epidermal necrolysis?

Increase the dose to overcome reduced erythropoiesis Continue treatment until antibody testing is complete Withdraw Aranesp immediately and do not restart it in a patient who developed SJS or TEN due to Aranesp Switch immediately to another epoetin without clinical evaluation

Question 6 of 10 Which factor is most directly relevant when evaluating whether a reported rapid haemoglobin increase may contribute to vascular risk?

The patient's blood group alone The serial haemoglobin trajectory and recent dose changes The colour of the injection device The date of the original marketing authorisation alone

Question 7 of 10 Which approach is most appropriate when assessing a report of suspected hypersensitivity to darbepoetin alfa?

Infer causality solely because symptoms followed an injection Reconstruct the clinical syndrome, timing and alternative explanations Classify every rash as anaphylaxis Assume that delayed symptoms cannot be treatment-related

Question 8 of 10 Why might a patient with chronic kidney disease show little haemoglobin improvement despite receiving an appropriate ESA dose?

ESAs replace iron and therefore make iron status irrelevant The ESA acts only on mature circulating red blood cells Iron restriction, inflammation, blood loss or other competing mechanisms may limit erythropoiesis Chronic kidney disease universally prevents erythroid progenitors from responding

Question 9 of 10 What central benefit-risk lesson is illustrated by the TREAT trial?

Reducing transfusions necessarily improves cardiovascular outcomes Higher haemoglobin targets may reduce transfusions while increasing stroke risk without improving major outcomes Placebo treatment completely prevents stroke in patients with chronic kidney disease Darbepoetin has no biological effect in patients with diabetes and chronic kidney disease

Question 10 of 10 What is the most appropriate therapeutic objective when using darbepoetin alfa in the settings described?

Normalize haemoglobin in every treated patient Achieve the highest possible haemoglobin before symptoms recur Use the lowest exposure that adequately controls symptoms and meets the treatment objective Maintain haemoglobin above the normal range to eliminate transfusion risk

QPPV.com

Darbepoetin Alfa: Erythropoietin Biology, Anaemia Treatment and Product Pharmacovigilance

Cookie Settings